{"id":"NCT03783442","sponsor":"BeiGene","briefTitle":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","officialTitle":"A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-11","primaryCompletion":"2022-02-28","completion":"2024-08-22","firstPosted":"2018-12-21","resultsPosted":"2023-11-07","lastUpdate":"2025-07-29"},"enrollment":649,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Esophageal Squamous Cell Carcinoma (ESCC)"],"interventions":[{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Oxaliplatin","otherNames":[]},{"type":"DRUG","name":"Fluorouracil (5-FU)","otherNames":[]},{"type":"DRUG","name":"Capecitabine","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"BIOLOGICAL","name":"Tislelizumab","otherNames":["BGB-A317","TEVIMBRA"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tislelizumab + Chemotherapy","type":"EXPERIMENTAL"},{"label":"Placebo + Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.","effectByArm":[{"arm":"Tislelizumab + Chemotherapy","deltaMin":17.2,"sd":null},{"arm":"Placebo + Chemotherapy","deltaMin":10.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":124,"countries":["United States","Australia","Belgium","China","Czechia","France","Germany","Italy","Japan","Poland","Romania","Russia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["37080222","40075024"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":160,"n":324},"commonTop":["Anaemia","Neutrophil count decreased","White blood cell count decreased","Decreased appetite","Nausea"]}}